Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.

Most patients with cutaneous dermatomyositis either improved or remained stable over 3.5 years.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Follicular dystrophy in immunocompromised patients may be linked to medication or viral factors and can improve with treatment changes.

DNA methylation of miR-365-1 causes hair follicle stem cell death by affecting DAP3.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Benign follicular mucinosis involves immune cells attacking hair follicles.

Tapering and stopping tofacitinib may be possible for young alopecia areata patients.

Scalp disease in dermatomyositis causes significant symptoms and has unique features.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

Linalool in personal care products may contribute to hair loss by damaging hair follicle stem cells and triggering harmful immune responses.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Tremella fuciformis polysaccharide has many health benefits and potential uses in food, medicine, and cosmetics.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.

Methotrexate and azathioprine are equally effective and well-tolerated for treating lichen planopilaris.

New drug delivery systems improve treatment effectiveness and patient experience.

A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.

Follicular mucinosis can be an early sign of aggressive mycosis fungoides.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

Fat tissue transplant may be an effective new treatment for severe, treatment-resistant hair loss from folliculitis decalvans.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.

Frontal fibrosing alopecia causes hairline recession and eyebrow loss in postmenopausal women.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Intralesional corticosteroids and 5-alpha-reductase inhibitors are the best treatments for frontal fibrosing alopecia.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Spanlastic nano-vesicles improve famotidine's effectiveness and absorption.

D-OCT shows increased blood vessel growth in response to tissue damage in Frontal Fibrosing Alopecia and is useful for diagnosis and monitoring.